Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Source
1.2.2. Cultivation
1.2.3. Derivatives
1.2.4. End-use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.2.1. Source outlook
2.2.2. Cultivation outlook
2.2.3. Derivatives outlook
2.2.4. End-use outlook
2.3. Competitive Landscape Snapshot
Chapter 3. Thailand Legal Cannabis Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing adoption of cannabis for treatment of chronic diseases
3.2.1.2. Growing demand for CBD-based products
3.2.1.3. Increasing preference for cannabis extracts such as oils and tinctures
3.2.1.4. Rising number of cannabis farms or cultivators in Thailand due to legalization
3.2.1.5. Rise in business expansion strategies to enter Thailand cannabis market
3.2.1.6. Structured regulatory framework and supportive reimbursement policies
3.2.2. Market Restraint Analysis
3.2.2.1. Introduction of a bill to amend the current cannabis legislation to ban its recreational use
3.2.3. Case Study Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTLE Analysis
3.4. Regulatory Landscape
Chapter 4. Thailand Legal Cannabis Market Segment Analysis, By Source, 2023-2032 (USD Million)
4.1. Definition and Scope
4.2. Source Segment Dashboard
4.3. Market Size & Forecasts and Trend Analyses, 2023-2032 for the following
4.4. Hemp
4.4.1. Market estimates and forecasts, 2023-2032 (USD Million)
4.4.2. Hemp Oil
4.4.2.1. Market estimates and forecasts, 2023-2032 (USD Million)
4.4.3. Industrial Hemp
4.4.3.1. Market estimates and forecasts, 2023-2032 (USD Million)
4.5. Marijuana
4.5.1.1. Market estimates and forecasts, 2023-2032 (USD Million)
4.5.2. Flower
4.5.2.1. Market estimates and forecasts, 2023-2032 (USD Million)
4.5.3. Oil and Tinctures
4.5.3.1. Market estimates and forecasts, 2023-2032 (USD Million)
Chapter 5. Thailand Legal Cannabis Market Segment Analysis, By Cultivation, 2023-2032 (USD Million)
5.1. Definition and Scope
5.2. Cultivation Segment Dashboard
5.3. Market Size & Forecasts and Trend Analyses, 2023-2032 for the following
5.4. Indoor Cultivation
5.4.1. Market estimates and forecasts, 2023-2032 (USD Million)
5.5. Greenhouse Cultivation
5.5.1. Market estimates and forecasts, 2023-2032 (USD Million)
5.6. Outdoor Cultivation
5.6.1. Market estimates and forecasts, 2023-2032 (USD Million)
Chapter 6. Thailand Legal Cannabis Market Segment Analysis, By Derivatives, 2023-2032 (USD Million)
6.1. Definition and Scope
6.2. Derivatives Segment Dashboard
6.3. Market Size & Forecasts and Trend Analyses, 2023-2032 for the following
6.4. CBD
6.4.1. Market estimates and forecasts, 2023-2032 (USD Million)
6.5. THC
6.5.1. Market estimates and forecasts, 2023-2032 (USD Million)
6.6. Others
6.6.1. Market estimates and forecasts, 2023-2032 (USD Million)
Chapter 7. Thailand Legal Cannabis Market Segment Analysis, By End-use, 2023-2032 (USD Million)
7.1. Definition and Scope
7.2. End-use Segment Dashboard
7.3. Market Size & Forecasts and Trend Analyses, 2023-2032 for the following
7.4. Industrial Use
7.4.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5. Medical Use
7.5.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5.2. Chronic Pain
7.5.2.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5.3. Depression and Anxiety
7.5.3.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5.4. Arthritis
7.5.4.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5.5. Post-Traumatic Stress Disorder (PTSD)
7.5.5.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5.6. Cancer
7.5.6.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5.7. Migraines
7.5.7.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5.8. Epilepsy
7.5.8.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5.9. Alzheimer’s
7.5.9.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5.10. Multiple Sclerosis
7.5.10.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5.11. Amyotrophic Lateral Sclerosis
7.5.11.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5.12. Tourette’s
7.5.12.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5.13. Diabetes
7.5.13.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5.14. Parkinson's
7.5.14.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5.15. Glaucoma
7.5.15.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.5.16. Others
7.5.16.1. Market estimates and forecasts, 2023-2032 (USD Million)
7.6. Recreational Use
7.6.1. Market estimates and forecasts, 2023-2032 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, by Key Market Participants
8.2. Company Categorization
8.3. Company Market Position Analysis
8.4. Company Profiles
8.4.1. PharmaHemp
8.4.1.1. Overview
8.4.1.2. Financial Performance
8.4.1.3. Service Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Tilray Brands
8.4.2.1. Overview
8.4.2.2. Financial Performance
8.4.2.3. Service Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Canopy Growth Corporation
8.4.3.1. Overview
8.4.3.2. Financial Performance
8.4.3.3. Service Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Medipharm Labs
8.4.4.1. Overview
8.4.4.2. Financial Performance
8.4.4.3. Service Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Epic Systems Corporation
8.4.5.1. Overview
8.4.5.2. Financial Performance
8.4.5.3. Service Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Cresco Labs
8.4.6.1. Overview
8.4.6.2. Financial Performance
8.4.6.3. Service Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Extractas
8.4.7.1. Overview
8.4.7.2. Financial Performance
8.4.7.3. Service Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. BOL Pharma
8.4.8.1. Overview
8.4.8.2. Financial Performance
8.4.8.3. Service Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Elixinol
8.4.9.1. Overview
8.4.9.2. Financial Performance
8.4.9.3. Service Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Dr. CBD Innovation Center
8.4.10.1. Overview
8.4.10.2. Financial Performance
8.4.10.3. Service Benchmarking
8.4.10.4. Strategic Initiatives
8.4.11. SAPPE
8.4.11.1. Overview
8.4.11.2. Financial Performance
8.4.11.3. Service Benchmarking
8.4.11.4. Strategic Initiatives
8.4.12. Osotspa Public Company Limited
8.4.12.1. Overview
8.4.12.2. Financial Performance
8.4.12.3. Service Benchmarking
8.4.12.4. Strategic Initiatives